Bonardelli P, Oliani C, Monici Preti P A, Pellicanó P, Quattrocchi G
Digestive Endoscopic Service, I.O.M.I. Institute Messina, Italy.
Clin Ther. 1990 Nov-Dec;12(6):547-55.
Thirty patients aged 26 to 70 years with a history of chronic osteoarthritis of at least eight years were randomly assigned to receive 20 mg daily of beta-cyclodextrin-piroxicam (beta-CDP) or tenoxicam for eight weeks. Both drugs effectively reduced pain, inflammation, and functional limitations of the affected joints. Endoscopy revealed minor posttreatment hemorrhagic lesions and erosions; these tended to be less severe in the group treated with beta-CDP than with tenoxicam. Slight to moderate gastrointestinal symptoms were reported by one patient treated with beta-CDP and three patients treated with tenoxicam; the symptoms were poorly correlated with endoscopic findings. It is concluded that both drugs are safe and effective in the control of symptoms in patients with chronic osteoarthritis.
30名年龄在26至70岁之间、患有至少八年慢性骨关节炎病史的患者被随机分配，每天接受20毫克的β-环糊精吡罗昔康（β-CDP）或替诺昔康治疗，为期八周。两种药物均有效减轻了患关节的疼痛、炎症和功能受限。内窥镜检查显示治疗后有轻微的出血性病变和糜烂；这些病变在接受β-CDP治疗的组中往往比接受替诺昔康治疗的组轻。接受β-CDP治疗的1名患者和接受替诺昔康治疗的3名患者报告有轻度至中度胃肠道症状；这些症状与内窥镜检查结果相关性较差。结论是，两种药物在控制慢性骨关节炎患者的症状方面都是安全有效的。
